This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 1 Dosing Study of BAX 513 in Healthy Volunteers

This study has been completed.
Information provided by:
Baxalta US Inc. Identifier:
First received: February 4, 2010
Last updated: June 26, 2015
Last verified: August 2010
The purpose of the study is to investigate whether orally administered BAX 513 (different doses administered for 5 days) affects hemostatic parameters in healthy volunteers.

Condition Intervention Phase
Not Applicable (Healthy Volunteers) Dietary Supplement: Fucoidan (extract of Laminaria japonica) Other: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers

Further study details as provided by Baxalta US Inc.:

Primary Outcome Measures:
  • Change in peak thrombin concentration from baseline as measured by the Thrombin Generation Assay (TGA). [ Time Frame: 7 months (= anticipated study duration) ]

Estimated Enrollment: 30
Study Start Date: January 2010
Study Completion Date: August 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BAX 513
Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
Dietary Supplement: Fucoidan (extract of Laminaria japonica)
Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
Other Name: BAX 513
Placebo Comparator: Capsule (cellulose)
Capsule - one of 5 dose levels (per randomization) - BID
Other: Placebo
Cellulose filled capsule - oral administration - 5 different dose levels - BID


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Is >= 18 and < 70 years old at the time of screening
  • Is able to provide signed and dated informed consent
  • Is a healthy male or female adult
  • If female and of childbearing potential, subject demonstrates a negative serum pregnancy test, and agrees to employ adequate birth control measures; (e.g., oral contraceptives, barrier method) for the duration of the study
  • If female and receiving hormone replacement therapy (HRT), subject agrees to abstain from HRT for the duration of the study
  • Subject's medical history and physical exam are normal
  • Subject's lab values for complete blood count (CBC) and clinical chemistry are within normal ranges
  • Is able to comprehend and comply with all aspects of the protocol and signed informed consent

Exclusion Criteria:

  • If female, subject is pregnant or lactating at the time of study enrollment
  • Has participated in another clinical study involving an investigational product (IP) or device within 30 days of screening or is scheduled to participate in another clinical study involving an IP or device during the course of this study
  • Has a history of drug allergy in general or hypersensitivity to fucoidan containing products/foods or seafoods
  • Medical and/or family history of thrombophilic tendencies, eg Protein C or S-deficiency, ATIII deficiency, FV Leiden mutation, Prothrombin 20210A mutation, lupus type inhibitor, antiphospholipid antibodies
  • Medical history or clinical findings of a significant bleeding disorder
  • Medical history of thrombotic events such as venous thromboembolism (VTE), myocardial infarction (MI), stroke or transient ischemic attack (TIA)
  • Any other clinically relevant history of disease, eg malabsorption disorders, malignancies
  • Any clinically significant abnormal laboratory values or abnormal ECG findings that in the opinion of the investigator are considered clinically relevant
  • Seropositivity for HBs-Ag, HCV, HIV-1 or HIV-2 antibodies
  • Symptoms of a clinically relevant illness within 3 weeks before screening
  • A history of, or suspected, drug or alcohol abuse, or subject tests positive on a Drugs of Abuse screen within 1 week of dosing
  • Intake of IP or related (fucoidan-containing) product within 1 week prior to study enrollment
  • Any planned surgical or dental procedure during the course of this study
  • Any recent surgery within 30 days of enrollment
  • Presence of signs or symptoms consistent with an infection, such as fever, chills, or nausea during screening in this study
  • Chronic or regular use of aspirin, ibuprofen, coumarin derivatives, antiplatelet drugs, within 1 week before enrollment
  • Use of concomitant drugs diclofenac or [paracetamol if > 2 g/day] within 1 week before first day of study dosing
  • Plasmapheresis or platelet donation within 3 weeks of screening and until final visit
  • Any medical condition that may compromise the ability to give written informed consent or to comply with the study protocol
  • Subject is a member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01063101

University Clinic for Clinical Pharmacology, General Hospital Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Baxalta US Inc.
Study Director: Wing-Yen Wong, MD Baxter Healthcare Corporation
  More Information

Responsible Party: Wing-Yen Wong, MD; Medical Director, Baxter Healthcare Corporation Identifier: NCT01063101     History of Changes
Other Study ID Numbers: 950901
Study First Received: February 4, 2010
Last Updated: June 26, 2015

Additional relevant MeSH terms:
Anti-Ulcer Agents
Gastrointestinal Agents
Antineoplastic Agents processed this record on August 18, 2017